Publication | Closed Access

Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma

Concurrent ChemoradiotherapyRadiation TherapyAnti-egfr AgentsMedicineCancer ManagementPathologyCancer TreatmentOncologyRadiation OncologyCancer ResearchAdvanced Nasopharyngeal Carcinoma